Hospital
Day Kimball Healthcare, INC.
Day Kimball Healthcare, INC. was paid $48.68M by Medicaid between Jan 2018 and Dec 2024, across 407 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoDAY KIMBALL HEALTHCARE, INC.
PUTNAM, CT 06260
PUTNAM, CT 06260
33aNPI1205056371assigned 04/30/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$48.68M
24GClaims1,674,411
24DCodes billed407
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Connecticut
Rank by total paid#8 of 18
Median peer was paid$15.60M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 320,263 | $6.78M | |
| 2019 | 258,100 | $7.01M | |
| 2020 | 199,748 | $5.84M | |
| 2021 | 228,948 | $7.58M | |
| 2022 | 230,992 | $7.85M | |
| 2023 | 237,442 | $7.61M | |
| 2024incomplete | 198,918 | $6.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 18,917 | 15,088 | $7.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.6% | 17,831 | 15,092 | $4.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 22,507 | 19,860 | $4.37M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.3% | 59,519 | 15,568 | $3.05M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 11,890 | 9,926 | $1.47M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 10,577 | 7,136 | $1.29M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.6% | 31,045 | 15,937 | $1.26M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 18,253 | 11,013 | $942K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 5,268 | 4,489 | $920K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.7% | 1,322 | 1,173 | $815K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 10,038 | 9,196 | $771K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.5% | 1,044 | 1,003 | $747K |
395 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 7,392 | $733K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 1,497 | $571K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 10,911 | $563K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.1% | 921 | $542K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 5,396 | $518K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 2,685 | $502K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,419 | $482K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 8,716 | $479K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 20,468 | $476K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,967 | $463K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,111 | $451K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,843 | $421K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,118 | $407K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 18,235 | $377K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,481 | $375K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,832 | $366K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 588 | $356K |
| 59025 | Fetal non-stress test | <1% | 2,291 | $344K |
| 62323 | <1% | 929 | $328K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,912 | $321K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,377 | $313K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,929 | $285K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,082 | $282K |
| 76830 | Ultrasound, transvaginal | <1% | 2,822 | $277K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 4,694 | $273K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,802 | $264K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,787 | $263K |
| 95811 | <1% | 405 | $259K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,655 | $254K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,826 | $235K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 542 | $232K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,628 | $231K |
| 86900 | <1% | 4,225 | $218K | |
| 97161 | <1% | 3,526 | $195K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 7,781 | $184K |
| 80053 | Comprehensive metabolic panel | <1% | 36,084 | $184K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,324 | $183K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,865 | $183K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,293 | $183K |
| 77065 | Tomosynthesis, mammo | <1% | 1,784 | $180K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,949 | $177K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 561 | $175K |
| 80061 | Lipid panel | <1% | 20,669 | $174K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 64,307 | $170K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,520 | $165K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 4,976 | $155K |
| 97162 | <1% | 3,153 | $154K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,142 | $152K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,048 | $149K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,129 | $142K |
| 36415 | Collection of venous blood by venipuncture | <1% | 98,637 | $126K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,873 | $119K |
| 86003 | <1% | 2,499 | $114K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12,517 | $112K |
| 76770 | <1% | 1,483 | $110K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,019 | $109K |
| 93350 | <1% | 526 | $108K | |
| 76536 | <1% | 1,439 | $107K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,292 | $106K |
| 94060 | <1% | 710 | $106K | |
| 72100 | <1% | 2,892 | $105K | |
| 76642 | <1% | 1,524 | $101K | |
| 87660 | <1% | 6,507 | $98K | |
| 87480 | <1% | 6,498 | $98K | |
| 87510 | <1% | 6,498 | $98K | |
| 97035 | <1% | 3,748 | $96K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,417 | $95K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,182 | $92K |
| 93971 | <1% | 1,455 | $90K | |
| 71250 | <1% | 1,410 | $87K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 297 | $85K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,057 | $84K |
| 86317 | <1% | 3,871 | $84K | |
| 77066 | Tomosynthesis, mammo | <1% | 738 | $80K |
| 73564 | <1% | 2,643 | $78K | |
| 93017 | <1% | 2,056 | $78K | |
| 96367 | <1% | 2,055 | $77K | |
| 97165 | <1% | 1,121 | $67K | |
| 88142 | <1% | 5,091 | $66K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,890 | $66K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,199 | $65K |
| 97014 | <1% | 852 | $64K | |
| 82607 | <1% | 6,752 | $63K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,522 | $60K |
| 86803 | <1% | 7,623 | $60K | |
| 73630 | <1% | 3,050 | $58K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,211 | $56K |
| 87088 | <1% | 17,184 | $56K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,668 | $55K |
| 83655 | <1% | 5,104 | $54K | |
| 82728 | <1% | 6,368 | $54K | |
| 76641 | <1% | 677 | $51K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,373 | $50K |
| 73030 | <1% | 2,498 | $49K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 311 | $48K |
| 85027 | <1% | 19,024 | $47K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 239 | $44K |
| 73610 | <1% | 2,337 | $42K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,972 | $41K |
| 82746 | <1% | 4,270 | $40K | |
| 87400 | <1% | 5,294 | $40K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 303 | $39K |
| 72141 | <1% | 203 | $37K | |
| 83550 | <1% | 6,900 | $36K | |
| 74018 | <1% | 1,154 | $36K | |
| 73130 | <1% | 1,971 | $35K | |
| 72052 | <1% | 466 | $34K | |
| 84439 | <1% | 5,382 | $33K | |
| 86704 | <1% | 3,706 | $32K | |
| 73110 | <1% | 1,600 | $31K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 67 | $31K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,441 | $29K |
| 86618 | <1% | 3,310 | $29K | |
| 73502 | <1% | 1,728 | $28K | |
| 84146 | <1% | 2,259 | $28K | |
| 87081 | <1% | 6,857 | $28K | |
| 87340 | <1% | 5,500 | $28K | |
| 83718 | <1% | 3,843 | $28K | |
| 83540 | <1% | 6,969 | $28K | |
| 29581 | <1% | 486 | $27K | |
| 97163 | <1% | 984 | $26K | |
| 70496 | <1% | 208 | $26K | |
| 86708 | <1% | 3,010 | $26K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 291 | $25K |
| 73560 | <1% | 630 | $25K | |
| 97116 | <1% | 1,949 | $23K | |
| 84403 | <1% | 1,140 | $23K | |
| 83970 | <1% | 1,047 | $23K | |
| 87077 | <1% | 5,912 | $21K | |
| 83516 | <1% | 1,546 | $21K | |
| 71271 | <1% | 243 | $21K | |
| 86706 | <1% | 2,765 | $21K | |
| 82040 | <1% | 8,830 | $21K | |
| 81001 | <1% | 28,753 | $20K | |
| 82247 | <1% | 8,642 | $20K | |
| 86592 | <1% | 6,091 | $20K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 323 | $20K |
| 0011A | <1% | 593 | $20K | |
| 87186 | <1% | 5,586 | $20K | |
| 72072 | <1% | 471 | $19K | |
| 0012A | <1% | 520 | $19K | |
| 84702 | <1% | 3,080 | $19K | |
| 19081 | <1% | 13 | $18K | |
| 83735 | <1% | 6,546 | $17K | |
| 87522 | Neg quan hep c or qual rna | <1% | 581 | $17K |
| 82105 | <1% | 1,464 | $17K | |
| 86480 | <1% | 384 | $17K | |
| 86038 | <1% | 2,238 | $17K | |
| 86850 | <1% | 4,253 | $15K | |
| 73221 | <1% | 85 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,491 | $15K |
| 88304 | <1% | 885 | $15K | |
| 85610 | <1% | 17,425 | $14K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 9,189 | $14K |
| 80076 | <1% | 12,977 | $14K | |
| 70486 | <1% | 230 | $12K | |
| 82043 | <1% | 3,599 | $12K | |
| 85651 | <1% | 6,210 | $12K | |
| 86140 | <1% | 4,007 | $11K | |
| 82570 | <1% | 3,923 | $11K | |
| 82310 | <1% | 8,775 | $11K | |
| 97016 | <1% | 399 | $11K | |
| 93271 | <1% | 185 | $10K | |
| 82784 | <1% | 1,168 | $10K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 412 | $10K |
| 85007 | <1% | 9,836 | $10K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,055 | $9K |
| 82947 | <1% | 8,845 | $9K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 337 | $9K |
| 83880 | <1% | 3,233 | $9K | |
| 83001 | <1% | 614 | $9K | |
| 73140 | <1% | 509 | $9K | |
| 87071 | <1% | 1,933 | $8K | |
| 80164 | <1% | 1,206 | $8K | |
| 84450 | <1% | 11,280 | $8K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 658 | $8K |
| 84402 | <1% | 369 | $7K | |
| 97012 | <1% | 228 | $7K | |
| 87147 | <1% | 2,250 | $7K | |
| 84153 | <1% | 779 | $7K | |
| 87184 | <1% | 2,208 | $7K | |
| 88342 | <1% | 218 | $7K | |
| 83690 | <1% | 10,006 | $7K | |
| 82950 | <1% | 1,719 | $6K | |
| 90785 | <1% | 791 | $6K | |
| 87073 | <1% | 1,570 | $6K | |
| 97166 | <1% | 175 | $6K | |
| 82465 | <1% | 3,858 | $5K | |
| 86431 | <1% | 1,522 | $5K | |
| 96523 | <1% | 190 | $5K | |
| 0001A | <1% | 132 | $5K | |
| 74183 | <1% | 28 | $5K | |
| 86762 | <1% | 2,142 | $5K | |
| 85730 | <1% | 3,481 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,447 | $5K |
| 86709 | <1% | 651 | $5K | |
| 0071A | <1% | 133 | $5K | |
| 77080 | <1% | 54 | $5K | |
| 0002A | <1% | 128 | $5K | |
| 0031A | <1% | 174 | $4K | |
| 87070 | <1% | 936 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,477 | $4K |
| 87205 | <1% | 2,319 | $4K | |
| 82652 | <1% | 141 | $4K | |
| 86756 | <1% | 822 | $4K | |
| 84550 | <1% | 3,040 | $4K | |
| 86617 | <1% | 268 | $4K | |
| 83630 | <1% | 348 | $3K | |
| 87420 | <1% | 1,096 | $3K | |
| 94726 | <1% | 699 | $3K | |
| 83721 | <1% | 508 | $3K | |
| 86376 | <1% | 338 | $3K | |
| 82248 | <1% | 3,304 | $3K | |
| 84156 | <1% | 1,876 | $3K | |
| 92523 | <1% | 22 | $3K | |
| 0072A | <1% | 82 | $3K | |
| 86255 | <1% | 284 | $3K | |
| 93018 | <1% | 456 | $3K | |
| 82374 | <1% | 8,285 | $3K | |
| 73080 | <1% | 204 | $3K | |
| 70491 | <1% | 26 | $3K | |
| 82550 | <1% | 1,822 | $3K | |
| 74019 | <1% | 231 | $3K | |
| 82565 | <1% | 9,828 | $3K | |
| 80069 | <1% | 411 | $3K | |
| 82670 | <1% | 116 | $3K | |
| 0064A | <1% | 72 | $2K | |
| 83525 | <1% | 246 | $2K | |
| 85379 | <1% | 2,972 | $2K | |
| 87521 | Neg quan hep c or qual rna | <1% | 81 | $2K |
| 71101 | <1% | 241 | $2K | |
| 80051 | <1% | 568 | $2K | |
| 84478 | <1% | 3,844 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 313 | $2K |
| 87427 | <1% | 305 | $2K | |
| 86200 | <1% | 200 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 86 | $2K |
| 85018 | <1% | 1,139 | $2K | |
| 0004A | <1% | 42 | $2K | |
| 85384 | <1% | 591 | $2K | |
| 73590 | <1% | 141 | $1K | |
| 87046 | <1% | 305 | $1K | |
| 86800 | <1% | 144 | $1K | |
| 87045 | <1% | 307 | $1K | |
| 81025 | <1% | 9,413 | $1K | |
| 86780 | <1% | 132 | $1K | |
| 84100 | <1% | 1,727 | $1K | |
| 80178 | <1% | 365 | $1K | |
| 82533 | <1% | 112 | $1K | |
| 84703 | <1% | 261 | $1K | |
| 87040 | <1% | 4,618 | $1K | |
| 85014 | <1% | 894 | $1K | |
| 84460 | <1% | 11,493 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,467 | $1K |
| 84436 | <1% | 413 | $1K | |
| 93243 | <1% | 14 | $1K | |
| 85045 | <1% | 559 | $1K | |
| 94762 | <1% | 12 | $1K | |
| 84484 | <1% | 14,828 | $1K | |
| 83021 | <1% | 507 | $913.72 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 72 | $905.70 |
| 36591 | <1% | 26 | $883.97 | |
| 83013 | <1% | 15 | $836.16 | |
| 73523 | <1% | 15 | $830.93 | |
| 83615 | <1% | 873 | $799.11 | |
| 93225 | <1% | 13 | $757.92 | |
| 70498 | <1% | 163 | $686.48 | |
| 88112 | <1% | 29 | $680.50 | |
| 86920 | <1% | 30 | $657.20 | |
| 84165 | <1% | 126 | $595.04 | |
| 83020 | <1% | 315 | $567.34 | |
| 83002 | <1% | 45 | $565.76 | |
| 82951 | <1% | 50 | $547.10 | |
| 73090 | <1% | 30 | $546.54 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,635 | $516.85 |
| 82150 | <1% | 151 | $476.63 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 858 | $454.74 |
| 86665 | <1% | 21 | $415.68 | |
| 82627 | <1% | 24 | $403.37 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 787 | $388.86 |
| 84479 | <1% | 117 | $321.36 | |
| 84132 | <1% | 8,403 | $317.23 | |
| 87449 | <1% | 90 | $305.08 | |
| 85660 | <1% | 525 | $283.29 | |
| J3490 | Unclassified drugs | <1% | 82,334 | $275.14 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 10,798 | $273.63 |
| 86308 | <1% | 104 | $271.70 | |
| 84481 | <1% | 28 | $226.52 | |
| 87209 | <1% | 30 | $223.25 | |
| 73070 | <1% | 16 | $207.38 | |
| 87329 | <1% | 42 | $194.65 | |
| 87328 | <1% | 42 | $194.65 | |
| 12001 | <1% | 67 | $182.41 | |
| 86664 | <1% | 12 | $175.32 | |
| 87177 | <1% | 30 | $161.50 | |
| 86663 | <1% | 12 | $150.36 | |
| 83883 | <1% | 14 | $142.78 | |
| 86334 | <1% | 14 | $131.51 | |
| 84520 | <1% | 9,446 | $123.02 | |
| 82435 | <1% | 8,285 | $112.35 | |
| 83605 | <1% | 1,131 | $104.26 | |
| 82785 | <1% | 14 | $94.38 | |
| 86005 | <1% | 14 | $91.44 | |
| 82952 | <1% | 24 | $86.02 | |
| 84155 | <1% | 8,575 | $80.50 | |
| 87324 | <1% | 31 | $80.15 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 912 | $79.86 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 123 | $77.70 |
| 82378 | <1% | 18 | $72.48 | |
| 86141 | <1% | 12 | $61.80 | |
| 82803 | <1% | 51 | $55.44 | |
| 82977 | <1% | 43 | $53.04 | |
| 90715 | <1% | 930 | $47.60 | |
| 82948 | <1% | 14,014 | $44.76 | |
| 93270 | <1% | 185 | $41.94 | |
| 90839 | <1% | 394 | $22.53 | |
| 84075 | <1% | 8,465 | $13.70 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,197 | $12.39 |
| 86901 | <1% | 4,224 | $10.65 | |
| 80047 | <1% | 6,068 | $8.17 | |
| 84295 | <1% | 8,291 | $6.23 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 73 | $0.32 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,781 | $0.20 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,558 | $0.12 |
| 91301 | <1% | 1,110 | $0.10 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 21 | $0.08 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 21 | $0.07 |
| 91300 | <1% | 344 | $0.01 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,548 | $0.01 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 295 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,018 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 836 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 3,589 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 3,779 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 1,801 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 1,894 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,801 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 11,072 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 645 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 63 | $0.00 |
| 94729 | 0% | 696 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 5,028 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 92 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 2,310 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 132 | $0.00 |
| 88312 | 0% | 175 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 340 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 316 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 372 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 88 | $0.00 |
| 29125 | 0% | 33 | $0.00 | |
| 94664 | 0% | 61 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 15 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 53 | $0.00 |
| 93226 | 0% | 13 | $0.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 35 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 2,915 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 210 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 6,099 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,403 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 4,108 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 4,759 | $0.00 |
| 96376 | 0% | 3,400 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 9,211 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 3,347 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 3,830 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,043 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 525 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,198 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,650 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 2,891 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 4,435 | $0.00 |
| 12002 | 0% | 16 | $0.00 | |
| 94750 | 0% | 500 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 1,314 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 112 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 60 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 25 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 430 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 660 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 6,139 | $0.00 |
| 36416 | 0% | 73 | $0.00 | |
| 91306 | 0% | 72 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 55 | $0.00 |
| 88307 | 0% | 15 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 110 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 101 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 53 | $0.00 |
| 88341 | 0% | 27 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 166 | $0.00 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 44 | $0.00 |
| 91307 | 0% | 215 | $0.00 | |
| 93242 | 0% | 14 | $0.00 | |
| 91303 | 0% | 173 | $0.00 | |
| J2650 | Injection, prednisolone acetate, up to 1 ml | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKRAMER, KYLE (CEO)
Parent organizationDAY KIMBALL HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Day Kimball Healthcare, INC. | Putnam, CT | $341K |
| Kramer Dental Anesthesia Services, INC. | Noblesville, IN | $129K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.